查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1751199

抗真菌药物市场规模、份额、趋势分析报告：按药物类别、适应症、剂型、分销管道、地区、细分市场预测，2025-2030 年

Antifungal Drugs Market Size, Share & Trends Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines), By Indication, By Dosage Form, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

抗真菌药物市场的成长与趋势：

根据 Grand View Research 的最新报告，到 2030 年全球抗真菌药物市场规模预计将达到 205.2 亿美元。

预计2025年至2030年，该市场将以3.92%的复合年增长率扩张。全球真菌感染疾病盛行率的上升是推动市场成长的关键因素。此外，近年来，由于免疫抑制剂和抗肿瘤药物、假体装置和植入物以及广谱抗生素的使用增加，真菌感染疾病的发生率也有所上升。

根据美国疾病管制与预防中心2017年发布的统计数据，全球每年新增近22万例隐球菌脑膜炎（一种脑部感染疾病）病例，估计每年导致18.1万人死亡。由于爱滋病毒/爱滋病的高发性，大多数死亡病例发生在撒哈拉以南非洲地区。这表明，由于全球真菌感染疾病的高发性，对抗真菌药物存在潜在的需求。

为遏止新冠肺炎疫情蔓延，许多国家的政府当局下令在全国实施封锁。同样，世界各地的卫生系统也在努力维持供应链。供应链延迟也影响了对抗真菌药物的需求。全球老龄人口的成长可能会刺激对抗真菌药物的需求，以治疗机会性真菌感染疾病，因为老年人更容易感染爱滋病毒和癌症等感染疾病和慢性病。由于难以诊断、死亡率和发病率高的真菌感染疾病增加，预计到2030年对抗真菌药物的需求仍将保持强劲。

抗真菌药物市场报告重点

  • Azole类药物将占据市场主导地位，2024 年的销售份额将达到 47.57%。这种主导地位是由于 Noxafil、Bufend、 Diflucan和 Cresemba 等主要治疗药物的影响。
  • 念珠菌症在 2024 年占据了最大的市场占有率，这是因为念珠菌病在免疫力缺乏的患者中的患病率不断增加，且復发性感染率很高。
  • 预计预测期内曲菌症的复合年增长率将显着提升。曲菌症是由一种名为曲菌症的霉菌引起的感染疾病，通常会影响呼吸系统。
  • 口服剂型在 2024 年占据市场主导地位。这是因为某些抗真菌药物是专为口服给药而设计的，以确保正确吸收。
  • 2024年，医院药局将引领市场。医院药房在确保患者即时获得基本药物方面发挥着至关重要的作用。它们服务于门诊病人和住院患者，促进真菌感染疾病的无缝治疗。
  • 北美将主导市场，到 2024 年将占据 40.62% 的份额。该地区的主导地位可归因于高度发展的医疗保健基础设施、可负担性和不断增强的意识。
  • 由于目标人口众多、市场不断扩大的医疗设施以及主要市场参与者的投资不断增加，预计亚太地区在预测期内将显着增长。

目录

第一章调查方法与范围

第二章执行摘要

抗真菌药物市场变数、趋势和范围

  • 市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

抗真菌药物市场：按药物类别的业务分析

  • 2024 年及 2030 年各药品类别的市场占有率
  • 药品类别细分仪表板
  • 2018-2030 年药品类别市场规模、预测及趋势分析
  • Azole
  • Echinocandins
  • Polyenes
  • Allylamines
  • 其他的

抗真菌药物市场：按适应症分類的业务分析

  • 2024 年及 2030 年各适应症市场占有率
  • 指示细分仪表板
  • 市场规模、预测与趋势分析（2018-2030 年）
  • 皮肤丝状菌症
  • 曲菌症
  • 念珠菌症
  • 其他的

抗真菌药物市场：按剂型分類的业务分析

  • 2024 年及 2030 年各剂型市场占有率
  • 剂型细分细分仪表板
  • 市场规模、预测与趋势分析（按剂型，2018-2030 年）
  • 口服药物
  • 软膏
  • 粉末
  • 其他的

抗真菌药物市场：按分销管道分類的业务分析

  • 2024 年和 2030 年按分销管道分類的市场占有率
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析（2018-2030 年）
  • 医院药房
  • 零售药局
  • 其他药局

抗真菌药物市场：区域估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018年至2030年市场规模与预测趋势分析：
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争态势

  • 参与企业概况
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/列表
    • Novartis AG
    • Pfizer, Inc.
    • Bayer AG
    • Sanofi
    • Merck &Co., Inc.
    • GSK plc.
    • Abbott
    • GLENMARK
    • Enzon Pharmaceuticals, Inc.
    • Astellas Pharma, Inc.
Product Code: GVR-1-68038-293-8

Antifungal Drugs Market Growth & Trends:

The global antifungal drugs market size is expected to reach USD 20.52 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 3.92% from 2025 to 2030. The increasing incidence of fungal infections worldwide is the key factor stoking the growth of the market. In addition, the rise in the adoption of immunosuppressive and antineoplastic agents, prosthetic devices and grafts, and broad-spectrum antibiotics has resulted in an increased incidence of fungal infections in recent years.

According to statistics published by the Centers for Disease Control and Prevention in 2017, it has been estimated that every year, nearly 220,000 new individuals are affected by cryptococcal meningitis, which is a brain infection and has resulted in 181,000 deaths per year around the world. Most of the deaths were reported in sub-Saharan Africa, due to the high prevalence of HIV/AIDS. This indicates the potential demand for antifungal drugs due to the high prevalence of mycological infections around the globe.

The government authorities in many countries had ordered nationwide lockdowns in order to contain the spread of COVID-19. Similarly, health systems in a number of countries around the world were having trouble maintaining their supply chains. The slowness of the supply chain has also impacted the demand for antifungal medications. As aged people are more prone to infectious diseases and chronic conditions, including HIV and cancer, the rise in the geriatric population worldwide is likely to stir up the demand for antifungals to treat opportunistic fungal infections. The demand for fungistatic agents is estimated to remain strong through 2030 due to mounting cases of fungal infections that are difficult to diagnose, yielding high mortality and morbidity rates.

Antifungal Drugs Market Report Highlights:

  • The Azoles drug class segment dominated the market and accounted for a revenue share of 47.57% in 2024. This dominance is attributed to the influence of key therapeutic agents, including noxafil, vfend, diflucan, and cresemba.
  • The Candidiasis segment held the largest market share in 2024 due to rising incidence of the disease in immunocompromised patients and high rate of recurrent infections.
  • Aspergillosis is expected to register significant CAGR during the forecast period. Aspergillosis is an infection caused by mold called aspergillosis, which usually affects the respiratory system.
  • Oral drugs dosage form led the market in 2024. This is attributed to the fact that certain antifungal medications are designed for oral administration to ensure proper ingestion.
  • Hospital pharmacies led the market in 2024. Hospital pharmacies play a key role in ensuring immediate access to crucial medications. They serve both out-patient and in-patient services, facilitating the seamless treatment of fungal infections.
  • North America dominated the market and accounted for 40.62% share in 2024. This region dominance is attributed to the highly developed healthcare infrastructure, better affordability, and increasing awareness.
  • Asia Pacific is anticipated to witness significant growth during the forecast period. This is owing to the presence of large target population, developing healthcare facilities, and increase in investments by leading market players.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Indication
    • 1.2.3. Dosage Form
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Antifungal Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Antifungal Drugs Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Azoles
    • 4.4.1. Azoles Market, 2018 - 2030 (USD Million)
  • 4.5. Echinocandins
    • 4.5.1. Echinocandins Market, 2018 - 2030 (USD Million)
  • 4.6. Polyenes
    • 4.6.1. Polyenes Market, 2018 - 2030 (USD Million)
  • 4.7. Allylamines
    • 4.7.1. Allylamines Market, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Other Drug Class Market, 2018 - 2030 (USD Million)

Chapter 5. Antifungal Drugs Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2024 & 2030
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 5.4. Dermatophytosis
    • 5.4.1. Dermatophytosis Market, 2018 - 2030 (USD Million)
  • 5.5. Aspergillosis
    • 5.5.1. Aspergillosis Market, 2018 - 2030 (USD Million)
  • 5.6. Candidiasis
    • 5.6.1. Candidiasis Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Antifungal Drugs Market: Dosage Form Business Analysis

  • 6.1. Dosage Form Market Share, 2024 & 2030
  • 6.2. Dosage Form Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2018 to 2030 (USD Million)
  • 6.4. Oral Drugs
    • 6.4.1. Oral Drugs Market, 2018 - 2030 (USD Million)
  • 6.5. Ointments
    • 6.5.1. Ointments Market, 2018 - 2030 (USD Million)
  • 6.6. Powders
    • 6.6.1. Powders Market, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Antifungal Drugs Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2030
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.6. Other Pharmacies
    • 7.6.1. Other Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Antifungal Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Antifungal Drugs Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. U.S. Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. Uk Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Japan Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. China Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Antifungal Drugs Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Novartis AG
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Pfizer, Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Bayer AG
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Sanofi
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Merck & Co., Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. GSK plc.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Abbott
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. GLENMARK
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Enzon Pharmaceuticals, Inc.
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Astellas Pharma, Inc.
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Antifungal drugs market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 5. Global antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 6. Global antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 7. Global antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8. North America antifungal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 9. North America antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 10. North America antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 11. North America antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 12. North America antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13. U.S. antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 14. U.S. antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 15. U.S. antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 16. U.S. antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17. Canada antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 18. Canada antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 19. Canada antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 20. Canada antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 21. Mexico antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 22. Mexico antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 23. Mexico antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 24. Mexico antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25. Europe antifungal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 26. Europe antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 27. Europe antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 28. Europe antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 29. Europe antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30. UK antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 31. UK antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 32. UK antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 33. UK antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34. Germany antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 35. Germany antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 36. Germany antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 37. Germany antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 38. France antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 39. France antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 40. France antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 41. France antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42. Italy antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 43. Italy antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 44. Italy antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 45. Italy antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 46. Spain antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 47. Spain antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 48. Spain antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 49. Spain antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50. Norway antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 51. Norway antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 52. Norway antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 53. Norway antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54. Denmark antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 55. Denmark antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 56. Denmark antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 57. Denmark antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58. Sweden antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 59. Sweden antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 60. Sweden antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 61. Sweden antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62. Asia Pacific antifungal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 63. Asia Pacific antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 64. Asia Pacific antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 65. Asia Pacific antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 66. Asia Pacific antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67. Japan antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 68. Japan antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 69. Japan antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 70. Japan antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71. China antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 72. China antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 73. China antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 74. China antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75. India antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 76. India antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 77. India antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 78. India antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79. Australia antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 80. Australia antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 81. Australia antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 82. Australia antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83. South Korea antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 84. South Korea antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 85. South Korea antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 86. South Korea antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87. Thailand antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 88. Thailand antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 89. Thailand antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 90. Thailand antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91. Latin America antifungal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 92. Latin America antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 93. Latin America antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 94. Latin America antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 95. Latin America antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 96. Brazil antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 97. Brazil antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 98. Brazil antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 99. Brazil antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 100. Argentina antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 101. Argentina antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 102. Argentina antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 103. Argentina antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 104. Middle East & Africa antifungal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 105. Middle East & Africa antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 106. Middle East & Africa antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 107. Middle East & Africa antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 108. Middle East & Africa antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 109. South Africa antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 110. South Africa antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 111. South Africa antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 112. South Africa antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 113. Saudi Arabia antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 114. Saudi Arabia antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 115. Saudi Arabia antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 116. Saudi Arabia antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 117. UAE antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 118. UAE antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 119. UAE antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 120. UAE antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 121. Kuwait antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 122. Kuwait antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 123. Kuwait antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 124. Kuwait antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Antifungal drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment snapshot
  • Fig. 10 Competitive landscape
  • Fig. 11 Antifungal drugs market dynamics
  • Fig. 12 Antifungal drugs market: Porter's five forces analysis
  • Fig. 13 Antifungal drugs market: PESTLE analysis
  • Fig. 14 Drug Class market, 2018 - 2030 (USD Million)
  • Fig. 15 Azoles market, 2018 - 2030 (USD Million)
  • Fig. 16 Echinocandins market, 2018 - 2030 (USD Million)
  • Fig. 17 Polyenes market, 2018 - 2030 (USD Million)
  • Fig. 18 Allylamines market, 2018 - 2030 (USD Million)
  • Fig. 19 Others market, 2018 - 2030 (USD Million)
  • Fig. 20 Indication market, 2018 - 2030 (USD Million)
  • Fig. 21 Dermatophytosis market, 2018 - 2030 (USD Million)
  • Fig. 22 Aspergillosis market, 2018 - 2030 (USD Million)
  • Fig. 23 Candidiasis market, 2018 - 2030 (USD Million)
  • Fig. 24 Others market, 2018 - 2030 (USD Million)
  • Fig. 25 Dosage Form market, 2018 - 2030 (USD Million)
  • Fig. 26 Oral Drugs market, 2018 - 2030 (USD Million)
  • Fig. 27 Ointments market, 2018 - 2030 (USD Million)
  • Fig. 28 Powders market, 2018 - 2030 (USD Million)
  • Fig. 29 Others market, 2018 - 2030 (USD Million)
  • Fig. 30 Distribution Channel market, 2018 - 2030 (USD Million)
  • Fig. 31 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 32 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 33 Other pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 34 Antifungal drugs market revenue, by region
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. country dynamics
  • Fig. 38 U.S. antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 39 Canada country dynamics
  • Fig. 40 Canada antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 41 Mexico country dynamics
  • Fig. 42 Mexico antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 43 Europe antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 44 UK country dynamics
  • Fig. 45 UK antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 46 Germany country dynamics
  • Fig. 47 Germany antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 48 France country dynamics
  • Fig. 49 France antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 50 Italy country dynamics
  • Fig. 51 Italy antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 52 Spain country dynamics
  • Fig. 53 Spain antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 54 Norway country dynamics
  • Fig. 55 Norway antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 56 Sweden country dynamics
  • Fig. 57 Sweden antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 58 Denmark country dynamics
  • Fig. 59 Denmark antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 61 Japan country dynamics
  • Fig. 62 Japan antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 63 China country dynamics
  • Fig. 64 China antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 65 India country dynamics
  • Fig. 66 India antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 67 Australia country dynamics
  • Fig. 68 Australia antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 69 South Korea country dynamics
  • Fig. 70 South Korea antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 71 Thailand country dynamics
  • Fig. 72 Thailand antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 73 Latin America antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 74 Brazil country dynamics
  • Fig. 75 Brazil antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 76 Argentina country dynamics
  • Fig. 77 Argentina antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 78 MEA antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 79 South Africa country dynamics
  • Fig. 80 South Africa antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 81 Saudi Arabia country dynamics
  • Fig. 82 Saudi Arabia antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 83 UAE country dynamics
  • Fig. 84 UAE antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 85 Kuwait country dynamics
  • Fig. 86 Kuwait antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 87 Company categorization
  • Fig. 88 Company market position analysis, 2024
  • Fig. 89 Strategic framework